Advent International, a private equity firm based in Boston, Massachusetts, is considering a buyout deal for drugmaker Swedish Orphan Biovitrum.
Advent has approached other buyout firms including Permira in an attempt to lead a consortium for the acquisition of the Swedish biotech firm.
Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.
It is also weighing to bring in sovereign wealth funds for the bid. The talks are at an early stage, and it is not yet clear that they will ultimately lead to a deal, according to the people.
Source: Seeking Alpha
Can’t stop reading? Read more
KKR exits aerospace supplier Novaria in $2.2bn sale to Arcline
KKR exits aerospace supplier Novaria in $2.2bn sale to Arcline KKR & Co. has agreed to sell...
Carlyle takes over UK retailer The Very Group, ending Barclay family era
Carlyle takes over UK retailer The Very Group, ending Barclay family era Carlyle Group has taken...
Permira takes JTC private in £2.3bn deal backed by Canada Pension Plan Investment Board
Permira takes JTC private in £2.3bn deal backed by Canada Pension Plan Investment Board Permira...